pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
Tour Hekla patents
0 pharmaceutical patents indexed for Tour Hekla. 0 expire within 24 months.
Tour Hekla has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Tour Hekla have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Tour Hekla patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.